(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -14.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Sarepta Therapeutics's revenue in 2026 is $2,198,237,000.On average, 27 Wall Street analysts forecast SRPT's revenue for 2026 to be $185,201,957,808, with the lowest SRPT revenue forecast at $145,515,823,992, and the highest SRPT revenue forecast at $208,404,697,420. On average, 25 Wall Street analysts forecast SRPT's revenue for 2027 to be $150,975,292,136, with the lowest SRPT revenue forecast at $90,891,745,416, and the highest SRPT revenue forecast at $206,619,871,296.
In 2028, SRPT is forecast to generate $153,495,046,664 in revenue, with the lowest revenue forecast at $110,239,260,600 and the highest revenue forecast at $202,840,239,504.